The use of aripiprazole (Abilify) to augment the response to antidepressant treatment is a common strategy. See Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole [Abilify] for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial [PubMed Abstract] [Full Text HTML] [Full Text PDF]. VOLUME 386, ISSUE 10011, P2404-2412, DECEMBER 12, 2015.
There are 237 articles similar to the above in PubMed.
What follows are some resources on aripiprazole (Abilify) and its association with Tardive Dyskinesia.
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1 [PubMed Abstract]. J Psychiatr Pract. 2015 Sep;21(5):359-69.
There are 177 articles similar to the above in PubMed.
There are 138 free full-text articles similar to the above in PubMed.
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept Studies [PubMed Abstract]. J Psychiatr Pract. 2016 Jan;22(1):42-9.
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data [PubMedAbstract]. J Psychiatr Pract. 2016 Mar;22(2):117-23.
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data [PubMed Abstract]. J Psychiatr Pract. 2016 May;22(3):203-20